Archive for the ‘
R&D Directions ’ Category
Thursday, May 6th, 2010
Med Ad News’ 19th annual report on the Top 100 Biotechnology Companies in our upcoming June issue will explore the impact of U.S. healthcare reform legislation on the biotech industry. Of particular note for the industry is a provision establishing the therapeutic discovery project tax credit.
The bill provides up to ...
Posted in
Legal actions, R&D Directions |
No Comments »
Tuesday, July 14th, 2009
Sermo claims that its break with the American Medical Association was driven by physicians' need for an alternative voice on critical healthcare issues by way of radical transparency. The AMA believes the value no longer warranted further participation and opted not to renew with Sermo in May. At the result ...
Posted in
Economy, Legal actions, Magazine production, R&D Directions, Technology, e-Marketing |
1 Comment »
Monday, June 29th, 2009
Since Med Ad News' diabetes therapeutic feature was published last month, questions regarding the safety of insulin analogues such as the insulin glargine Lantus have surfaced. Now diabetes drug marketers Sanofi-Aventis SA and Novo Nordisk AS are engaged in rapid-fire PR initiatives to back the clinical evidence of their products.
On ...
Posted in
Adwise, DTC advertising, Legal actions, Magazine production, Patient education, Professional education, R&D Directions, e-Marketing |
No Comments »
|
|
